General Clinical Chemistry Analyzers and Accessories
Abcam Sitravatinib, 25MG
MW 629.7 Da, Purity =98%. Broad spectrum receptor tyrosine kinase inhibitor (e.g. Axl, c-Met, PDGFR, VEGFR, Ephrin receptor family, and FLT3). Better efficacy in mouse models than imatinib and crizotinib.
The product is subject to the following: Abcam Restricted Use Statement
Abcam IWP-4, 50MG
MW 496.6 Da, Purity >98%. Potent inhibitor of Wnt pathway regulatory protein porupine (Porcn). Blocks Wnt protein secretion and prevents the canonical and non-canonical signaling pathways. Blocks palmitylation, and subsquent secretion and activity of Wnt. Induces differentiation of cardiomyocytes from human ESCs and iPSCs.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Fluorescein di-ß-D-glucuronide, dimethyl ester, 2MG
MW 712.61 g/mol, Purity >95%. Sensitive, cell-permeant β-glucuronidase substrate for live cell and tissue assays of cloned GUS marker gene activity and transfection levels.
The product is subject to the following: Abcam Restricted Use Statement
Abcam PF-04929113 (SN x -5422), 50MG
MW 521.5 Da, Purity >99%. Potent and selective Hsp90 inhibitor (IC₅₀ = 50 nM). A Her-2 degradation inducer (IC₅₀ = 37 nM).
The product is subject to the following: Abcam Restricted Use Statement
Abcam TW-37, 50MG
MW 573.7 Da, Purity >98%. Small-molecule inhibitor of BCL-2 (Ki = 0.29 μM). Inhibits multiple BCL-2 family members including BCL-XL (Ki = 1.11 μM) and MCL-1 (Ki= 0.26 μM). Binds to the BCL-2 homology domain 3 (BH3) groove of BCL-2. Significant anti-proliferative and pro-apoptotic activity in lymphoma cells.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Adaphostin, 5MG
MW 393.5 Da, Purity >=98%. Adaphostin is a p210bcr/abl tyrosine kinase inhibitor (IC50 = 14 μM) that displays anti-proliferative activity in leukemia models, human prostate cancer cell line PC-3 and other cancer cell lines. Adaphostin is a potent inducer of myeloid cell death.
The product is subject to the following: Abcam Restricted Use Statement
Abcam ML-385, 25MG
MW 511.6 Da, Purity >=98%. A potent and selective Nrf2 inhibitor (Nrf2; IC₅₀ = 1.9 μM). ML-385 blocks Nrf2 downstream target gene expression. ML-385 displays specificity and selectivity for NSCLC cells with KEAP1 mutation, which leads to gain of Nrf2 function.
The product is subject to the following: Abcam Restricted Use Statement
Abcam LCL161, 10MG
MW 500.6 Da, Purity >99%. Small molecule SMAC mimetic inhibitor of multiple IAP (Inhibitor of apoptosis) family proteins. (IC₅₀ = 10.23 μM). Inhibits cell proliferation and viability in two human hepatocellular carcinoma cells (Hep3B, IC₅₀ = 10, and PLC5, IC₅₀ = 19).
The product is subject to the following: Abcam Restricted Use Statement
Abcam PF-04929113 (SN x -5422), 100MG
MW 521.5 Da, Purity >99%. Potent and selective Hsp90 inhibitor (IC₅₀ = 50 nM). A Her-2 degradation inducer (IC₅₀ = 37 nM).
The product is subject to the following: Abcam Restricted Use Statement
Abcam SGI1776, 10MG
MW 405.4 Da, Purity >99%. Novel ATP competitive inhibitor of Pim1 with IC50 of 7 nM, 50- and 10-fold selective versus Pim2 and Pim3. Preliminary results from studies treating prostate cancer cells.
The product is subject to the following: Abcam Restricted Use Statement
Abcam TW-37, 10MG
MW 573.7 Da, Purity >98%. Small-molecule inhibitor of BCL-2 (Ki = 0.29 μM). Inhibits multiple BCL-2 family members including BCL-XL (Ki = 1.11 μM) and MCL-1 (Ki= 0.26 μM). Binds to the BCL-2 homology domain 3 (BH3) groove of BCL-2. Significant anti-proliferative and pro-apoptotic activity in lymphoma cells.
The product is subject to the following: Abcam Restricted Use Statement
Abcam BIIB 021, 25MG
MW 318.76 Da, Purity >98%. Selective, Hsp90 competitive inhibitor (Ki = 1.7 nM). Displays no significant activity at a range of ATP-binding kinases or Na+K+ ATPase. Induces degradation of HER-2 in vitro (EC₅₀ = 38 nM in MCF-7 cells). Inhibits growth and promotes cell death in a variety of human tumor cells. Orally bioavailable.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Ispinesib (SB-715992), 10MG
MW 517.1 Da, Purity >98%. A potent, selective and reversible allosteric inhibitor of KSP with IC₅₀ value of 0.5 nM. Often combines with chemotherapy drugs to tumor treatment.
The product is subject to the following: Abcam Restricted Use Statement
Abcam BMS-986142, 1MG
MW 572.6 Da, Purity >=98%. BMS-986142 is a potent, selective, and reversible BTK (Bruton's tyrosine kinase) inhibitor (BTK IC₅₀ = 0.5nM; human WB IC₅₀ = 90 nM). BMS-986142 displays robust efficacy in murine models of rheumatoid arthritis (RA), including collagen-induced arthritis (CIA) and collagen antibody-induced arthritis (CAIA).
The product is subject to the following: Abcam Restricted Use Statement
Abcam GLPG-1690, 5MG
MW 588.7 Da, Purity >=98%. Selective autotaxin inhibitor with potential application in idiopathic pulmonary disease (IPF).
The product is subject to the following: Abcam Restricted Use Statement